These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28918425)

  • 41. External validation of leukocytosis and neutrophilia as a prognostic marker in anal carcinoma treated with definitive chemoradiation.
    Schernberg A; Huguet F; Moureau-Zabotto L; Chargari C; Rivin Del Campo E; Schlienger M; Escande A; Touboul E; Deutsch E
    Radiother Oncol; 2017 Jul; 124(1):110-117. PubMed ID: 28662871
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of pelvic chemoradiation therapy in patients with initially metastatic anal canal cancer: A National Cancer Database review.
    Abdelazim YA; Rushing CN; Palta M; Willett CG; Czito BG
    Cancer; 2019 Jun; 125(12):2115-2122. PubMed ID: 30825391
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
    Zimmermann M; Beer J; Bodis S; von Moos R; Vlachopoulou V; Zwahlen DR; Oehler C
    Acta Oncol; 2017 Dec; 56(12):1734-1740. PubMed ID: 28557585
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Definitive Chemoradiation in Locally Advanced Squamous Cell Carcinoma of the Hypopharynx: Long-term Outcomes and Toxicity.
    Juloori A; Koyfman SA; Geiger JL; Joshi NP; Woody NM; Burkey BB; Scharpf J; Lamarre EL; Prendes B; Adelstein DJ; Greskovich JF; Keller L
    Anticancer Res; 2018 Jun; 38(6):3543-3549. PubMed ID: 29848708
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease.
    Fraunholz IB; Haberl A; Klauke S; Gute P; Rödel CM
    Dis Colon Rectum; 2014 Apr; 57(4):423-31. PubMed ID: 24608297
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term outcomes following neoadjuvant chemoradiotherapy in patients with clinical T2N0 esophageal squamous cell carcinoma.
    Chen WH; Chao YK; Chang HK; Tseng CK; Wu YC; Liu YH; Hsieh MJ; Liu HP
    Dis Esophagus; 2012 Apr; 25(3):250-5. PubMed ID: 21951719
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Role of Multiagent Chemoradiation in the Management and Prognosis of Anal Squamous Cell Carcinoma.
    Goffredo P; Utria AF; Hrabe JE; Gribovskaja-Rupp I; Kapadia MR; Hassan I
    J Gastrointest Surg; 2019 Apr; 23(4):712-719. PubMed ID: 30644029
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hyperfractionated Accelerated Reirradiation for Patients With Recurrent Anal Cancer Previously Treated With Definitive Chemoradiation.
    Osborne EM; Eng C; Skibber JM; Rodriguez-Bigas MA; Chang GJ; Nancy You YQ; Bednarski BK; Minsky BD; Delclos ME; Koay E; Krishnan S; Crane CH; Das P
    Am J Clin Oncol; 2018 Jul; 41(7):632-637. PubMed ID: 27755060
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment Outcome of Anal Squamous Cell Carcinoma Treated with Radical Chemoradiotherapy].
    Sato H; Koide Y; Shiota M; Morise Z; Maeda K; Uyama I
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1708-1710. PubMed ID: 28133106
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The assessment of local response using magnetic resonance imaging at 3- and 6-month post chemoradiotherapy in patients with anal cancer.
    Kochhar R; Renehan AG; Mullan D; Chakrabarty B; Saunders MP; Carrington BM
    Eur Radiol; 2017 Feb; 27(2):607-617. PubMed ID: 27090113
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy.
    Rödel F; Steinhäuser K; Kreis NN; Friemel A; Martin D; Wieland U; Rave-Fränk M; Balermpas P; Fokas E; Louwen F; Rödel C; Yuan J
    Radiother Oncol; 2018 Feb; 126(2):214-221. PubMed ID: 29122359
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patterns of failure and outcome in patients with carcinoma of the anal margin.
    Khanfir K; Ozsahin M; Bieri S; Cavuto C; Mirimanoff RO; Zouhair A
    Ann Surg Oncol; 2008 Apr; 15(4):1092-8. PubMed ID: 18231838
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
    Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Local excision versus radical surgery for anal squamous cell carcinoma: a multicenter study in Japan.
    Murai S; Nozawa H; Yamada K; Saiki Y; Sasaki K; Murono K; Emoto S; Matsuzaki H; Yokoyama Y; Abe S; Nagai Y; Yoshioka Y; Shinagawa T; Sonoda H; Sugihara K; Ajioka Y; Ishihara S
    Int J Clin Oncol; 2024 Jun; 29(6):813-821. PubMed ID: 38526623
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis.
    Dasgupta T; Rothenstein D; Chou JF; Zhang Z; Wright JL; Saltz LB; Temple LK; Paty PB; Weiser MR; Guillem JG; Nash GM; Goodman KA
    Radiother Oncol; 2013 May; 107(2):189-94. PubMed ID: 23692961
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal.
    Schiller DE; Cummings BJ; Rai S; Le LW; Last L; Davey P; Easson A; Smith AJ; Swallow CJ
    Ann Surg Oncol; 2007 Oct; 14(10):2780-9. PubMed ID: 17638059
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chemoradiation versus local excision in treatment of stage I anal squamous cell carcinoma: A population-based analysis.
    Gao X; Goffredo P; Kahl AR; Charlton ME; Weigel RJ; Hassan I
    Eur J Surg Oncol; 2020 Sep; 46(9):1663-1667. PubMed ID: 32199768
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin.
    Sebag-Montefiore D; Meadows HM; Cunningham D; Plowman PN; Hurman DC; Davidson N; Grieve R; Levine E; Glynne-Jones R
    Radiother Oncol; 2012 Aug; 104(2):155-60. PubMed ID: 22857859
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
    James RD; Glynne-Jones R; Meadows HM; Cunningham D; Myint AS; Saunders MP; Maughan T; McDonald A; Essapen S; Leslie M; Falk S; Wilson C; Gollins S; Begum R; Ledermann J; Kadalayil L; Sebag-Montefiore D
    Lancet Oncol; 2013 May; 14(6):516-24. PubMed ID: 23578724
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Polo-like kinase 3 and phosphoT273 caspase-8 are associated with improved local tumor control and survival in patients with anal carcinoma treated with concomitant chemoradiotherapy.
    Rödel F; Martin D; Helmke C; Balermpas P; Fokas E; Wieland U; Rave-Fränk M; Kitz J; Matthess Y; Raab M; Strebhardt K; Rödel C
    Oncotarget; 2016 Aug; 7(33):53339-53349. PubMed ID: 27462786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.